Med Tech & Diagnostics Analyst Matson, along with Dr. John Carter, Medical Director of the MetroHealth Inspire Sleep Program at The MetroHealth System, discuss obstructive sleep apnea (OSA) treatments (relevant companies INSP, LIVN, NYXH, PHG, RMD) including he impact of GLP-1 drugs, SURMOUNT-OSA trial results, CPAP products, hypoglossal nerve stimulation (HNS) products, and ApniMed’s OSA drug on an Analyst/Industry conference call to be held on July 9 at 2 pm.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSP: